Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCXN80)

Drug Name
Tozorakimab Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute respiratory failure CB41.0 Phase 3 [1]
Chronic obstructive pulmonary disease CA22 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMCXN80

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-33 (IL33) TT5MD4P IL33_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-33 (IL33) DTT IL33 5.162 4.096 3.053 3.954
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute respiratory failure
ICD Disease Classification CB41.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-33 (IL33) DTT IL33 1.19E-01 -0.03 -0.03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05624450) A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health.
3 ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 31;21(1):691.